Abstract
Background
Male breast cancer is a rare malignant tumor, and outcomes of breast conservation
therapy (BCT) are currently lacking.
Method
The retrospective, population-based cohort study included 1369 stage I-II (T1–2 N0–1
M0) male breast cancer patients from the SEER database (2000-2018). The patients were
grouped in two groups: BCT group and mastectomy group, according to surgical and radiation
therapy. Kaplan-Meier method and univariable Cox proportional hazard analysis were
used to compare overall survival (OS) and breast cancer-specific survival (BCSS) between
two treatment groups. Propensity score matching (PSM) was performed to balance the
confounding factors.
Results
Of the 1369 men, 97 (7%) patients received BCT, 1272 (93%) received mastectomy alone.
The 5- and 10-year OS rates were 92.3% and 80.7% for BCT group compared with 80.4%
and 61.4% for mastectomy group. The 5- and 10-year BCSS rates were 96.5% and 93.9%
for patients undergoing BCT, as compared with 93.1% and 84.4% for patients undergoing
mastectomy. Compared with mastectomy group, BCT group showed improved OS (hazard ratio
[HR], 0.294; 95% CI 0.138-0.623, P = .002) and BCSS (hazard ratio [HR], 0.182; 95% CI 0.040-0.820, P = .027). Of the 791 patients with T1 stage, BCT showed insignificant association
with OS (hazard ratio [HR], 0.555; 95% CI 0.207-1.488, P = .242) and BCSS (hazard ratio [HR], 1.217; 95% CI 0.171-8.675, P = .844).
Conclusion
The results of this cohort study suggest that BCT is at least equivalent to mastectomy
in male breast cancer patients. The underlying mechanism of this association needs
further research.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Breast CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cancer statistics, 2020.CA Cancer J Clin. 2020; 70: 7-30
- Management of male breast cancer: ASCO guideline.J Clin Oncol. 2020; 38: 1849-1863
William JG, Meena SM, Jame A, et al. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Version 1. 2022. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed.
- Molecular characterization and mortality from breast cancer in men.J Clin Oncol. 2018; 36: 1396-1404
- Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.Ann Oncol. 2018; 29: 405-417
- The biology of male breast cancer.Breast. 2018; 38: 132-135
- Male breast cancer: a closer look at patient and tumor characteristics and factors that affect survival using the National Cancer Database.Breast Cancer Res Treat. 2020; 180: 471-479
- Evolving surgical treatment decisions for male breast cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database.Breast Cancer Res Treat. 2018; 171: 427-434
- Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer.N Engl J Med. 2002; 347: 1233-1241
- Male Breast Cancer in the United States: Treatment patterns and prognostic factors in the 21st century.Cancer. 2020; 126: 26-36
- Surgery for men with breast cancer: do the same data still apply?.Ann Surg Oncol. 2020; 27: 4720-4729
- Is breast-conserving therapy appropriate for male breast cancer patients? A National Cancer Database Analysis.Ann Surg Oncol. 2019; 26: 2144-2153
- Locoregional treatment and overall survival of men with T1a,b,cN0M0 breast cancer: a population-based study.Eur J Cancer. 2017; 71: 7-14
- Outcomes of partial mastectomy in male breast cancer patients: analysis of SEER, 1983-2009.Ann Surg Oncol. 2013; 20: 1545-1550
- Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer.N Engl J Med. 1985; 312: 665-673
- Trend and survival benefit of contralateral prophylactic mastectomy among men with stage I-III unilateral breast cancer in the USA, 1998-2016.Breast Cancer Res Treat. 2021; 190: 503-515
- Should adjuvant radiation therapy be systematically proposed for male breast cancer? A systematic review.Anticancer Res. 2018; 38: 23-31
- Breast conserving surgery compared with mastectomy in male breast cancer: a brief systematic review.Clin Breast Cancer. 2020; 20 (e309-e314)
- Adjuvant tamoxifen adherence in men with early-stage breast cancer.Cancer. 2021; 128: 59-64
- The role of radiation therapy in addition to lumpectomy and hormone therapy in men 70 years of age and older with early breast cancer: a NCDB analysis.Ann Surg Oncol. 2021; 28: 2463-2471
Article Info
Publication History
Published online: March 30, 2022
Accepted:
March 27,
2022
Received in revised form:
March 25,
2022
Received:
January 21,
2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
